



UTAH STATE SENATE

UTAH STATE CAPITOL COMPLEX • 320 STATE CAPITOL
P.O. BOX 145115 • SALT LAKE CITY, UTAH 84114-5115 • (801) 538-1035

January 18, 2023

Mr. President,

The Health and Human Services Committee recommends **S.B. 16**, SEX CHARACTERISTIC SURGICAL PROCEDURES, by Senator M. S. Kennedy, be replaced and reports a favorable recommendation on **1st Sub. S.B. 16**, TRANSGENDER MEDICAL TREATMENTS AND PROCEDURES AMENDMENTS with the following amendments:

1. *Page 1, Line 14 through 15:*

14 ▶ requires the Department of Health and Human Services ~~{to study}~~ to
 conduct a systematic review of the medical evidence regarding hormonal
15 transgender treatments and provide recommendations to the Legislature;

2. *Page 2, Line 48 through 56:*

48 26B-1-214. {Study} Systematic medical evidence review of hormonal
 transgender treatments.

49 (1) As used in this section, "hormonal transgender treatment" means the same as that

50 term is defined in Section 58-1-603.

51 (2) The department, in consultation with the Division of Professional Licensing
 created

52 in Section 58-1-103, the Physicians Licensing Board created in Section 58-67-201, the

53 Osteopathic Physician and Surgeon's Licensing Board created in Section 58-68-201,

~~{and}~~ the

Bill Number



SB0016S01

Action Class



S

Action Code



SCRSUBAMD

54 University of Utah, **and a non-profit hospital system that has multiple hospitals**
located in Utah and experience in specialty pediatric care, shall conduct a ~~{study~~
-}
systematic medical evidence review regarding the provision of hormonal
transgender
55 treatments to minors.
56 (3) The purpose of the ~~{study}~~ **systematic medical evidence review** is
to provide the Legislature with recommendations to

3. *Page 3, Line 58 through 60:*

58 (4) The ~~{study}~~ **systematic medical evidence review** shall:
59 (a) analyze hormonal transgender treatments that are prescribed to a minor with
gender
60 dysphoria, including:

4. *Page 3, Line 80 through 81:*

80 (5) Upon the completion of the ~~{study}~~ **systematic medical evidence**
review, the department shall provide the ~~{study}~~ **systematic medical**
evidence review to the
81 Health and Human Services Interim Committee.

5. *Page 4, Line 114 through Page 5, Line 122:*

114 (ii) "Hormonal transgender treatment" does not include administering, prescribing,
or
115 supplying a substance described in Subsection (1)(e)(i) to an individual if the treatment is
116 medically necessary as a treatment for:
117 (A) precocious puberty;
118 ~~{(B) idiopathic short stature;}~~
119 ~~{(C)}~~ **(B)** endometriosis;

120	(D)	<u>(C)</u>	<u>a menstrual, ovarial, or uterine disorder;</u>
121	(E)	<u>(D)</u>	<u>a sex-hormone stimulated cancer; or</u>
122	(F)	<u>(E)</u>	<u>a disorder of sexual development.</u>

Respectfully,

Michael S. Kennedy
Chair

Voting: 5-2-0

5 SB0016.SC1.wpd 1/18/23 4:10 pm markandrews/MDA CW1/MDA